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Coronary reperfusion early atIer the onset of acute myo- 
cardiai inbrction can restore vessel patency, improve ven- 
tricuiar function and reduce short- and lung-term murtai- 
ity. A number of reperfusior,l methods have been used to 
achieve vessel patency in acute mymzardiai infarction, hut 
each strategy varies considerably in its risk to the patient. 
Intravenous thromboiysis is associated with an 8% risk of 
major or  minor bieeding and a ~0.5% risk of intracranial 
bieeding. This latter risk has been reported to be 1.5% 
when 150 rather than 100 mg of intravenous recombinant 
tissue-type piasminogen activator @t-PA) is used. Invasive 
procedures such as cardiac catheterization, coronary angio- 
piasty and intraaortic baiioon pumping signiticantiy in- 
creased the risk of major bieeding at the vascular entry site 
(from 20 to 40%). Clinical factors such as dder age, female 
gender, lower body weight and hematoiogic variables in- 
cluding nadir fibrinogen levels and fibrin degradation prod-  
ucts also relate to an increased risk. 
Coronary angiopiasty performed alone without throm- 
bolysts is not associated with an excess risk of bieeding and 
appears to have compiications similar to those reported for 
angiopbuty in patients undergoing elective procedures. 
Systemk antkoaguiation has a low (<2%) imhience of 
bieeding, and seriws bieeding is rare. These risks must be 
considered in the de&km to institute a treatment strategy 
in patients with acute myucardial infarction. 
(J Am Coil Cardiol1988;l%:SZA-7A) 
Thromboiytic therapy has been accepted as standard treat- 
ment for selected patients with acute myocardiai infarction. 
When thromboiytic agents are given early after the onset of 
chest pain, clinicai trials (i-5) have shown that their use 
restores coronary vessel patency, improves regional and 
global left ventricular function and reduces short- and long- 
term mortality. When a clinician is faced with a decision to 
institute thromboiytic therapy, consideration must be given 
not only to its potential benefits, but also to the inherent 
risks involved. 
A number of treatment strategies are currently used in 
patients with acute myocardial infarction. To dale, clinical 
trials have examined the use of thrombolytic therapy alone, 
thrombolytic agents combined with immediate angiopiasty, 
thromboiysis with delayed angiopiasty. angiopiasty alone 
and prolonged anticoagulation. The latter intervention has 
been primarily restricted to patients who are deemed unsuit- 
able for other interventional approaches. The currently 
available published reports indicate that the risks of these 
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strategies are widely divergent and should be considered in 
deciding on a treatment plan for any individual patient. 
Thrombolytic Therapy 
Contraindications. In understanding the potential risks of 
thrombolytic agents, it is important to recognize that many 
patients are not candidates for treatment with these drugs 
because of absolute or relative contlaindications. Although 
no data are available on the exact risk in many of their 
situations, clinical trials have adopted a number of criteria 
for excluding patients from thromboiytic therapy on the 
basis of clinical intuition. These have included presence of 
an active bleeding disorder or diathesis, a history of cere- 
brovascuiar accident or disease and severe hypertension 
(diastolic blood pressure >I20 mm Hg) (2-5). In addition, 
patient age >75 years, acute hypertension, the presence of 
pregnancy or recent surgery or trauma, concurrent oral 
anticoagulanr therapy or have also been thought to increase 
the risk of blecdinq and are relative contraindications to the 
use of thromboly:lc agents (2-5). As reported by the Gruppo 
Italian0 per lo Shtdio della Streptochinasi nell’lnfarto Mio- 
cardic J (GISSI) (3) and Intravenous Streptokinase in Acute 
Myocardial Infarction (ISAM) (5) trials, approximately 15% 
of patients have a contraindication to thromboiytic therapy. 
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National Heart, Lung, and Blood Institute’s Thrombolysis in 
Myocardial Infarction trial (TBMI-1 study). the incidence of 
major and minor bleeding wes similar with intravenous rt-PA 
and streptokinase (Table 2). Because all patients underwent 
cardiac catheterization in that study. it is not surprising that 
the catheterization entry site was the major source of bleed- 
ing with each agent, and that such bleeding occurred in 
>I% of patients. The major difference between the groups 
was a significant reduction in fibrinogen in nearly one-third 
of the patients given streptokinase. 
Addi/iond reports of bleeding t omplicurions from de 
T/MI rrid also indicate that the dose of r&PA is linked to the 
incidence of bleeding. As reported by Mueller et al. (13). the 
highest risk occurred when I50 mg of the single chain rt-PA 
was givett, as evidenced by evidence of bleeding in 64% of 
patients and the need for transfusion In 31% (Table 3). Of 
importance i\ that in both the TIM14 trial (12)  and the dosing 
trial (I 3). aJ patients underwent immediate cardiac catheter- 
ization and the catheterization entry site proved to be the 
most common scurce of significant bleeding. The incidence 
of bleeding in these trials was significantly greater than that 
Table 2. Inctdence of Hemorrhagic Events After Inlravenous 
rt-PA or  Streptokinase (TIMI-I) (13)  
I&PI\ I”rl SK WI 
Lvcm ,6 = 1431 ,” = 147)  
Type af blmd lo\=, 
hbJW 15.4 15.6 
MIIW 17.5 IS.6 
Slk 
Inlr.crdnldl 0 0 
Of cathetermuon 27 3 212 
Of other puncture 4.9 4.1 
GJ\l~Olllt~\llIl.d 4.9 6.8 
Gen~tounnary 6.3 1.4 
Rclruperllonudi 0.7 0.7 
Tmnsruwn 2.4 19.7 
Flbrmogen T NH) mgldl 3.0 30.0 
-  
rl.PA = recumbmant tissue plasmmogen acI~valer: SK = Wplokma~e. 
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Table 3. Bleeding Complications Associated With Incremental Doses of II-PA* (TIMI) (13)  
Study NO. Dose (mg) lntervcntiont Major (%6) (ICI Minor (%) Transfusion (%) 
I 113 80 Calh 15.4 (0)  17.5 22.4 
A 47 so Cath ll.oto) 16.0 15.0 
R 83 loo Cath 20.0(1.1) 22.0 23.0 
C 62 I50 Carh 24.0 (0)  42.0 31.0 
Total 305 17.0 23.0 23.0 
‘The two chain n~olecule form of r&PA: tcardiac ca~heterizadon V&h) was performed at 90 min akr rl-PA to 
assess vesxl patency. IC = intracranial bleeding: No. = number of padents: rl.PA = recombinant tissue-type 
plasminogeo acdvB1or; Tlhtl = Thmmbolysis in Myocardial Infarction hial. 
reported in patients receiving thrombolytic agents and not 
undergoing cardiac catheterization. Likewise, the dose of 
&PA is also related to the most serious bleeding complica- 
tion, namely intracranial bleeding. The iacidence of intra- 
cranial bleeding has been reported (14) to be 0.4% in patients 
given 100 mg of single chain rt-PA; however, the incidence is 
sigmficantly (1.6%) higher in patients given 150 mg Al- 
though few details are available about the clinical character- 
istics of these patients, it appears that several clinical factors 
are associated with an increased risk. namely, elderly age, 
female gender and elevated diastolic blood pressure or 
history of hypertension or prior neurologic events (14). 
Role of degree offibrinogen depletion. Mueller et al. (13) 
also pointed out that, in part, excess b!:eding could be 
predicted by the degree of the systemic lytic state as shown 
by the level of fibrin degradation products. A 73% incidence 
rate of major and minor bleeding was noted when fibrin 
degradatton products exceeded 400 &ml, but was only 30% 
when fibrin degradation products were -=XW &ml. Like- 
wise, the degree of fibrinogen depletion also paralleled 
bleeding risks. Although these hematologic variables relate 
to bleeding complications with r&PA, they do not relate 
hematologically with streptokinase. One explanation for this 
difference is that r&PA is a relatively clot-specific agent that 
would be expected to result in systemic fibrinolysis only 
when large doses are given. This contrasts with the nonse- 
lective actinn of streptokinase, which results in a systemic 
tibrogenoiytic state at therapeutic doses. 
Risk of ninfarction. This has been reported to be higher 
after patients have undergone thrombolysis than in patients 
treated by conventional therapy (Table I). In the GlSSl trial 
(3). the incidence rate was 4.1% compared with 2.1% for the 
control group. This is not surprising because thrombolytic 
therapy results in greater vessel patency and is likely to 
increase the risk of reocclusion and reinfarction. Although 
the incidence of reinfarction is low, angiographic studies 
(4,15,16) have shown that reocclusion is more common, 
ranging from IO to 45% (average 20%) in previous studies of 
intracoromuy streptokinase. Several studies (17,18) have 
reported that the risk of reocclttsion or reinfarction is related 
to the residual stenosis after thrombolysis. In a study by 
Harrison et al. (17), in the I1 patients with a residual stenosis 
>0.4 mm*, no reocclusion occurred, whereas 7 of 13 patients 
had reocclusion when the residual stenosis was CO.4 mm*. 
Similarly, Grhtes et al. (IS) reported that, in paiients treated 
with &PA, the combination of poor coronary anterograde 
flow (TIM1 grade 2), intermittent patency and a residual 
stenosis >50% occurred in 90% of those who exhibited 
reocclusion. 
Thromboiysis and Angiopbsty 
The use of adjunct angioplasty has been shown to result 
in greater vessel patency than that achieved by thrombolysis 
alone. In addition, a less stenotic residual lesion occurs, 
which may reduce the risk of subsequent ischemia (15,1!9- 
22). A greater improvement in left ventricular function and a 
further reduction in mortality had been previously antici- 
pated; however, the results of the TAM1 (23). TIM1 (24) and 
European Cooperative (25) trials have not documented this 
Table 4. Results of Randomized Trials of Tbrombolysi: and Immediate Angioplasty 
Ejection 
Monalily (%) Fraction t%) Bleeding t%) Reinfarcdon (%I 
-  -  -  - - -  
Study (reference) No. T C T C T C T C 
Meyere, al. (23)  190 13 7 51 54 NR NR 5 13 
Topal el al. (24)  386 4 I 53 54 5 42 II 13 
Simoons et al. (25)  361 1 3 51 51 41 23 4 7 
TIMI-IIA 389 77 5.2 50 49 19.5 7.2 5.6 3.1 
C = thrombolysis only: No. = number of patients; NR = nol reported; T = treatment group receiving 
thrombolysis and immediale angioplwy. 
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25 pattents requiring emergency bypass surgery in the 2 h 
angiopla\ty group. 
The rerrrlf~ of !hu TIMI trial 124)  cho confirmed these 
/indieps. In 3R6 patients receiving r&PA and undergoing 
immediate cardiac catheterization, Califf et al. (27)  reported 
a multivariate analysis of clinical and hematotogic features. 
The analysis showed that the more invastve the approach, 
the greater the risk of major bleeding. Overall, there was a 
14% ircidence rate of significant bleeding and a 31% inci- 
dence rate of transfusion requirements of 22 U. The highest 
risk occurred in patients undergoing coronary bypass sur- 
gery after thrombolytic therapy. In patients who did not 
undergo emergency surgery. the risk of overt bleeding was 
related to emergency angioplasty and the use of an intraaor- 
tic balloon. The clinical variables related to bleeding were 
lower body weight, older age. female gender and a history of 
hypertension. Nadir fibrinogen and plasminogen activator 
inhibitor levels were also related to an increased risk of 
hemorrhage. It is also important to note that all patients 
underwent catheterization in the study, and thus the findings 
that angioplasty imparts additional risk beyond cardiac cath- 
eterization is important. Although the reasons for this in- 
creased risk are unknown, they may be related IO a longer 
dumtion of the procedures and use of large femoral intro- 
ducing catheters and additional heparinization. The inci- 
dence rate of reinfarction (Table 4)  in !hese trials is similar to 
that of thrombolysis alone anJ ranges from 4 to III. 
Angioplasty 
Coronary angioplasty alone. in the absence of thrombo- 
lytic agents. has a much lower incidence of complications. 
with the risk of bleeding being very low (<2%) and primarily 
related to local entry site bleeding, without the need for 
transfusions (20.26.28.29) (TableSt. Other risks include the 
risk of reocclusion, which appears to be similar to that with 
thrombolysis alone, and the risk of restenosis. which ap 
pears to be similar to that with anpioplasty in patients in 
stable condition (30.31) As there have been no randomized 
trials Jirectly comparing intravenous thrombolysis with 
angioplasty alone, it is not possible to assess the risk of 
angioplasty in patients with acute myocardial infarction. 
From the currently available reports, however, the overall 
mortality appears to be similar to that reported for patients 
receiving thrombolytic therapy alone. 
Anticoagulation 
Perhaps the least risky intervention in patients with acute 
myocardial infarction is intravenous or  oral anticoagulant 
therapy. Nearly all trials of thrombolytic therapy have 
incorporated prolonged heparinizatron after the administra- 
tion of a thrombolytic agent to reduce the risk of reocclu- 
Gon. For that reason, it is difficult to separate the specific 
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Table 5. Complications of Immediate Coronary Angioplasty Without Thrombolysis in Acute 
Myocardial Infarction 
Study (reference) No. 
Angiographic 
S0ccess (%) Death (%) 
Emergency 
CABG (%I Reocclu5ion Reslenoris 
Sriram et al. (28)  R 87 0 0 0 0 
Holmes et al. (29)  II 91 0 0 0 NR 
O’Neill et al. (30)  29 85 7 0 3.4 NR 
Hartzler et al. (21)  29 loo 0 0 5 I2 
Rothbaum et al. (31)  151 85 9 5.3 9 31 
Williams et al. (26)  62 87 6.5 9.7 9.9 N R  
CABG = coronary artery bypass grail surgery; No. = number of pahents: N R  = not reported. 
contribution of heparin from that of the thrombolytic agent 
in assessiug the risk of bleeding. In several recent trials 
(5.8.9.25). control patients did not receive a thrombolytic 
agent and were treated with either warfarin, as was the case 
in the early Eurowan Cooperative trial (8). or prolonged 
heparinization, as was the c&e in the more recent ‘Europian 
Cooperative trial (25). the ISAM trial (5) and the New 
Zealand trial reported by White et al. (9). The incidence of 
significant bleeding in these trials, including minor bleeding 
at puncture sites, was very low, averaging <2% (range I to 
2.6). and none of the patients developed any intracranial 
bleeding. 
Summary 
The risk of the currently employed strategies for the 
mortality. reinfarclion and sidesRects from 33 randomized controlled 
trials. Ear Heart ! 1985;6:SJMS. 
2. Simoons ML, van den Brand M. DeZwaans C. et al. Improved survival 
after early lhrombolysis in acute myocardial infarction. A randomized 
lrial by the Intro-University Cardiology Institute in the Nelherlaed~. 
Lancel 198.WS78-82. 
treatment of patients with acute myocardial infarction varies 
widely. The majcr complicatior! of thiombolysis is sponta- 
ncous bleeding, which can occur in approximately 8% of 
patients, with serious bleeding occurring in ~2%. Throm- 
bolysis combined with immediate angioplasty has a signifi- 
cantly greater risk of bleeding, which is further increased 
when emergency bypass surgery is performed in this setting. 
In some studies, this risk may be as nigh as 40%. Angio- 
plastp alone is not associated with excess risk of bleeding, 
and appears to have risks similar IO those with angioplasty 
performed in patients in stable condition, including a 30% 
incidence of restenosis. Anticoagulation appears to be the 
least harmful intervention, with significant bleeding occur- 
ring ti c~nly a sqall percent of patients. These strategies, 
modulated by individual patient characteristics, can dramat- 
ically affect the incidence of serious complications. The 
adverse consequences of these treatment strategies must be 
taken into consideration and balanced against any potential 
benent when making a decision to institute a given therapy in 
any individual patient with acute myocardial infarction. 
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